Trials / Completed
CompletedNCT06343636
A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Vigil Neuroscience, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VG-3927 | Dose Escalation |
| DRUG | Placebo | Dose Escalation |
| DRUG | VG-3927 | One Dose Level |
Timeline
- Start date
- 2023-09-22
- Primary completion
- 2025-01-10
- Completion
- 2025-01-10
- First posted
- 2024-04-02
- Last updated
- 2025-02-07
Locations
3 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06343636. Inclusion in this directory is not an endorsement.